BioSpace News Archive

Quest Diagnostics Incorporated (NYSE: DGX) announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company’s strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time.

Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the results of resolutions presented at its Combined General Meeting, held on December 20, 2023 and made them available on the dedicated section of its website.

Nuvalent, Inc. (Nasdaq: NUVL) today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 7:30 a.m. PT in San Francisco.

Mallinckrodt plc, a global specialty pharmaceutical company, recently announced the publication of findings from a cost analysis of TERLIVAZ® for injection for adults with hepatorenal syndrome with rapid reduction in kidney function.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST.

Merck and Eisai announce that KEYTRUDA® plus LENVIMA® is now reimbursed with clinical criteria and conditions under the British Columbia, Alberta, Saskatchewan, Ontario, Quebec, Nova Scotia, New Brunswick, and Newfoundland drug plans, for adult patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd., is gearing up for participation in the JP Morgan 42nd Annual Healthcare Week, scheduled to run from January 8 to 11, 2024, in San Francisco.

Exscientia plc announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration.